Table 2 Signal strength of drugs associated with melasma adverse reactions from the FAERS database (meeting criteria of all four disproportionality analysis methods)
DRUG | CaseNumbers | ROR(95%Cl) | PRR(χ2) | EBGM(EBGM05) | IC(IC025) |
|---|---|---|---|---|---|
Ethinylestradiol and norethindrone | 7 | 204.8(96.96-432.57) | 204.48(1393.52) | 201.05(107.55) | 7.65(5.98) |
Ethinylestradiol and norelgestromin | 44 | 184.65(135.07-252.44) | 184.42(7175.69) | 164.97(126.99) | 7.37(5.69) |
Ethinylestradiol and levonorgestrel | 10 | 148.94(79.5-279.03) | 148.78(1432.49) | 145.22(85.88) | 7.18(5.51) |
Ethinylestradiol and norgestimate | 6 | 110.47(49.32-247.43) | 110.38(640.95) | 108.8(55.41) | 6.77(5.09) |
Ethinylestradiol and desogestrel | 3 | 83.06(26.67-258.71) | 83.01(241.32) | 82.42(31.86) | 6.36(4.69) |
Conjugated estrogens and medroxyprogesterone acetate | 6 | 42.61(19.03–95.43) | 42.6(240.23) | 42(21.39) | 5.39(3.72) |
Ethinylestradiol and drospirenone | 34 | 35.78(25.19–50.81) | 35.77(1054.91) | 32.92(24.54) | 5.04(3.37) |
Encorafenib | 3 | 27.76(8.91–86.43) | 27.75(76.81) | 27.56(10.65) | 4.78(3.11) |
Levonorgestrel | 66 | 26.71(20.53–34.75) | 26.71(1373.39) | 22.62(18.15) | 4.5(2.83) |
Conjugated estrogens | 5 | 16.3(6.75–39.38) | 16.3(70.95) | 16.12(7.71) | 4.01(2.34) |
Estradiol | 10 | 15.9(8.49–29.77) | 15.9(136.23) | 15.54(9.19) | 3.96(2.29) |
Ethinylestradioland etonogestrel | 7 | 14.24(6.75–30.06) | 14.24(84.71) | 14.02(7.5) | 3.81(2.14) |
Metronidazole | 5 | 14.05(5.82–33.94) | 14.05(59.88) | 13.89(6.64) | 3.8(2.12) |
Clarithromycin | 4 | 10.45(3.9-27.99) | 10.45(33.87) | 10.36(4.55) | 3.37(1.7) |
Finasteride | 5 | 9.79(4.05–23.64) | 9.79(38.97) | 9.68(4.63) | 3.28(1.6) |
Medroxyprogesterone acetate | 3 | 8.61(2.76–26.8) | 8.61(20.02) | 8.55(3.31) | 3.1(1.42) |
Isotretinoin | 8 | 8.58(4.26–17.28) | 8.58(52.57) | 8.44(4.7) | 3.08(1.4) |
Anastrozole | 3 | 7.44(2.39–23.17) | 7.44(16.6) | 7.39(2.86) | 2.89(1.21) |
Ribavirin | 3 | 7.33(2.35–22.82) | 7.33(16.28) | 7.28(2.82) | 2.86(1.19) |
Paroxetine | 8 | 6.49(3.22–13.06) | 6.49(36.42) | 6.38(3.55) | 2.67(1) |
Abemaciclib | 5 | 6.49(2.68–15.66) | 6.48(22.92) | 6.42(3.07) | 2.68(1.01) |
Imatinib | 7 | 5.92(2.8-12.49) | 5.92(28.11) | 5.83(3.12) | 2.54(0.87) |